A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
Latest Information Update: 11 Dec 2024
Price :
$35 *
At a glance
- Drugs VC 005 (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Vcare Pharmatech
- 11 Dec 2024 New trial record